Phillip A. Sharp, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 55,642 shares at $230.71 ($12.8M) on 2022-08-15, disclosed to the SEC on 2022-08-17.
Open-market sale of $12.8M ALNY by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $226.16 | 98 | $22K | 0.2% |
| 2 | $228.33 | 1,218 | $278K | 2.2% |
| 3 | $228.33 | 1,218 | $278K | 2.2% |
| 4 | $229.93 | 11,600 | $2.7M | 20.8% |
| 5 | $230.71 | 16,186 | $3.7M | 29.1% |
| 6 | $230.71 | 16,186 |
| $3.7M |
| 29.1% |
| 7 | $231.65 | 3,853 | $893K | 7.0% |
| 8 | $231.65 | 3,853 | $893K | 7.0% |
| 9 | $232.81 | 715 | $166K | 1.3% |
| 10 | $232.81 | 715 | $166K | 1.3% |
| Total | $230.62 avg | 55,642 | $12.8M | 100% |
| Filing → |
| ALNY | SELL | 2022-02-11 | $4.5M | — | Filing → |
| ALNY | SELL | 2020-11-30 | $7.5M | — | Filing → |
| ALNY | SELL | 2020-02-13 | $3.9M | — | Filing → |